Natural products targeting secondary pathological mechanisms in Duchenne muscular dystrophy: a scoping review

Duchenne muscular dystrophy (DMD) is caused by dystrophin deficiency and is accompanied by interconnected secondary pathological processes, including chronic inflammation, oxidative stress, impaired muscle regeneration, fibrosis, mitochondrial dysfunction, calcium dysregulation, and vascular dysfunction. Natural products have been investigated as experimental modulators of several of these processes, but the evidence is heterogeneous in intervention type, model, exposure, and outcome. A systematic search of PubMed, Scopus, Web of Science, ScienceDirect, and Cochrane Library (2015–2024) identified studies evaluating natural products (NPs) in DMD models. Data were analyzed focusing on the molecular mechanisms of action and pharmacological outcomes. Twenty-one primary studies met the DMD-specific criteria after two non-DMD-model reports were excluded from the initially charted 23 records. The eligible evidence was predominantly preclinical, with one small clinical pilot that included a DMD subgroup. Based on reconciled outcome charting, inflammation (12/21), oxidative stress (8/21), regeneration (12/21), fibrosis (10/21), and mitochondrial-related processes (4/21) were represented; these overlapping counts require final primary-paper verification. Direct compounds, complex formulations, delivery adjuncts, and ex vivo cell-expansion reagents were considered separately. The literature maps natural-product interventions to multiple secondary mechanisms relevant to DMD, but it remains predominantly preclinical and methodologically heterogeneous. The current evidence does not establish DMD-specific clinical efficacy, long-term safety, corticosteroid-sparing effects, or a role in standard care. Future work should use prospectively defined DMD models and outcomes, transparent pharmacokinetic and safety reporting, and adequately powered DMD-specific clinical studies.

Authors

Institutions

Publication Details

Journal
Skeletal Muscle
Published
2026-11-18
DOI
https://doi.org/10.1186/s13395-026-00461-2
Primary Topic
Muscle Physiology and Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Natural products targeting secondary pathological mechanisms in Duchenne muscular dystrophy: a scoping review

Min Seok Kim, Maic Audo Eybi Mayer Sihombing, Young Sook Kim
3 links
Skeletal Muscle
Muscle Physiology and Disorders
article

Natural products targeting secondary pathological mechanisms in Duchenne muscular dystrophy: a scoping review

Min Seok Kim, Maic Audo Eybi Mayer Sihombing, Young Sook Kim
article en

Abstract

Duchenne muscular dystrophy (DMD) is caused by dystrophin deficiency and is accompanied by interconnected secondary pathological processes, including chronic inflammation, oxidative stress, impaired muscle regeneration, fibrosis, mitochondrial dysfunction, calcium dysregulation, and vascular dysfunction. Natural products have been investigated as experimental modulators of several of these processes, but the evidence is heterogeneous in intervention type, model, exposure, and outcome. A systematic search of PubMed, Scopus, Web of Science, ScienceDirect, and Cochrane Library (2015–2024) identified studies evaluating natural products (NPs) in DMD models. Data were analyzed focusing on the molecular mechanisms of action and pharmacological outcomes. Twenty-one primary studies met the DMD-specific criteria after two non-DMD-model reports were excluded from the initially charted 23 records. The eligible evidence was predominantly preclinical, with one small clinical pilot that included a DMD subgroup. Based on reconciled outcome charting, inflammation (12/21), oxidative stress (8/21), regeneration (12/21), fibrosis (10/21), and mitochondrial-related processes (4/21) were represented; these overlapping counts require final primary-paper verification. Direct compounds, complex formulations, delivery adjuncts, and ex vivo cell-expansion reagents were considered separately. The literature maps natural-product interventions to multiple secondary mechanisms relevant to DMD, but it remains predominantly preclinical and methodologically heterogeneous. The current evidence does not establish DMD-specific clinical efficacy, long-term safety, corticosteroid-sparing effects, or a role in standard care. Future work should use prospectively defined DMD models and outcomes, transparent pharmacokinetic and safety reporting, and adequately powered DMD-specific clinical studies.

Skeletal Muscle
Korea Institute of Oriental Medicine (KR), Dongguk University WISE (KR), Korea University of Science and Technology (KR)
Korea Institute of Oriental Medicine
Good health and well-being
Muscle Physiology and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon